Compare AGM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | NRIX |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | AGM | NRIX |
|---|---|---|
| Price | $149.71 | $15.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $215.00 | $30.58 |
| AVG Volume (30 Days) | 78.8K | ★ 996.4K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $10.89 | $26.32 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $136.57 | $8.18 |
| 52 Week High | $210.64 | $22.50 |
| Indicator | AGM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 50.71 |
| Support Level | $146.69 | $14.31 |
| Resistance Level | $164.32 | $16.47 |
| Average True Range (ATR) | 4.51 | 0.83 |
| MACD | 1.28 | 0.11 |
| Stochastic Oscillator | 80.96 | 67.87 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.